COMING SOON
Frequently Asked Questions
COMING SOON
Browse through medical articles
Medical-on-the-Go: 2025 ATOS Study
July 2025
Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL.
Medical-on-the-Go: ADA 2025 Congress Updates
July 2025
The ADA 2025 Congress featured significant developments in diabetes management, with Simon Heller chairing an important session on measuring hypoglycemia burden and severity in diabetes patients.
Medical-on-the-Go: ATTD 2025 Congress Updates
April 2025
Medical-on-the-Go is happy to share highlights from the recently concluded ATTD Congress 2025 Last March 19-22, 2025 in Amsterdam & online.
Medical-on-the-Go: The Soli-D RCT
September 2024
We would like to update you on a recently published randomized, head-to-head, open label phase 3 trial in Chinese people with Type 2 Diabetes Mellitus suboptimally controlled on OADs entitled the Soli-D study.
Medical-On-The-Go: Malik Study
June 2024
This real-world observational study by Malik et al. shows that initiation of iGlarLixi in people with T2D suboptimally controlled on OADs ± BI or GLP-1 RAs improves glycemic control with a low incidence of hypoglycaemia.
Browse through on-demand medical videos
Exploring Gla-300 use in individuals with renal impairment Video-on-Demand
May 2025
Our global expert highlights that individuals living with Type 2 diabetes (T2D) and renal impairment are a key high-risk population and additional considerations need to be made in the management of diabetes.
Listen through medical discussions
Medical-On-The-Go: Soli-D Podcast
April 2025
In this episode, we delve into the Efficacy and safety of iGlarLixi versus IDegAsp in Chinese adults with type 2 diabetes, based on the findings from the Soli-D randomized controlled trial.
Medical-On-The-Go:Time in Range Podcast
February 2025
In this episode, Dr Jeremy Pettus and Dr Steve Edelman discuss the increasing role of continuous glucose monitoring (CGM) and time-in-range (TIR) in diabetes management.
Browse through different medical cources
COMING SOON
Explore upcoming medical events
COMING SOON
Explore medical resources
COMING SOON
For General Inquires – Contact us
Adverse events & product safety
If you experience any adverse event, i.e., any unfavorable and unintended sign (an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medical product, please email it to PV.Philippines@sanofi.com
To report a product technical complaint, please contact our Quality Affairs team:
- Voicemail (non-business hours): +632-8859-5555 extension #1
- Email: Philippines.PTC@sanofi.com
For Data Privacy requests and concerns:
Sanofi General Medicines (under sanofi-aventis Philippines, Inc.) and Sanofi Vaccines (under Sanofi Pasteur, Inc.): OneTrust
For General Inquires – Contact us
Adverse events & product safety
If you experience any adverse event, i.e., any unfavorable and unintended sign (an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medical product, please email it to PV.Philippines@sanofi.com
To report a product technical complaint, please contact our Quality Affairs team:
- Voicemail (non-business hours): +632-8859-5555 extension #1
- Email: Philippines.PTC@sanofi.com
For Data Privacy requests and concerns:
Sanofi General Medicines (under sanofi-aventis Philippines, Inc.) and Sanofi Vaccines (under Sanofi Pasteur, Inc.): OneTrust
For General Inquires – Contact us
Adverse events & product safety
If you experience any adverse event, i.e., any unfavorable and unintended sign (an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medical product, please email it to PV.Philippines@sanofi.com
To report a product technical complaint, please contact our Quality Affairs team:
- Voicemail (non-business hours): +632-8859-5555 extension #1
- Email: Philippines.PTC@sanofi.com
For Data Privacy requests and concerns:
Sanofi General Medicines (under sanofi-aventis Philippines, Inc.) and Sanofi Vaccines (under Sanofi Pasteur, Inc.): OneTrust